Pilot experience with opebacan/rBPI 21 in myeloablative hematopoietic cell transplantation.

Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation (1974) 10.91

Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med (2001) 5.59

Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol (2003) 5.46

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet (2000) 4.81

Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol (1999) 3.44

Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol (1999) 2.85

Cytokine dysregulation and acute graft-versus-host disease. Blood (1992) 2.43

Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood (2000) 2.40

Cell-wall-deficient bacteria and culture-negative febrile episodes in bone-marrow-transplant recipients. Lancet (2001) 2.37

High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun (1992) 2.17

Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest (1998) 2.14

LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest (2001) 1.91

Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J Clin Invest (1992) 1.82

Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol (2008) 1.65

Regulation of interactions of Gram-negative bacterial endotoxins with mammalian cells. Immunol Res (2007) 1.63

Separation of sublethal and lethal effects of the bactericidal/permeability increasing protein on Escherichia coli. J Clin Invest (1990) 1.52

Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant? Infect Immun (2007) 1.50

The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease. J Endotoxin Res (2002) 1.37

Antimicrobial proteins and peptides: anti-infective molecules of mammalian leukocytes. J Leukoc Biol (2004) 1.28

Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation (2000) 1.27

Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). Philos Trans R Soc Lond B Biol Sci (2005) 1.26

Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transplant (2007) 1.21

Antibacterial proteins of granulocytes differ in interaction with endotoxin. Comparison of bactericidal/permeability-increasing protein, p15s, and defensins. J Immunol (1995) 1.05

Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation. Blood (2005) 1.00

A neutrophil-derived anti-infective molecule: bactericidal/permeability-increasing protein. Antimicrob Agents Chemother (2000) 0.98

Bactericidal/permeability-increasing protein (rBPI21) and fluoroquinolone mitigate radiation-induced bone marrow aplasia and death. Sci Transl Med (2011) 0.98

Recombinant bactericidal/permeability-increasing protein rBPI21 protects against pneumococcal disease. Infect Immun (2006) 0.98

Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI. Ann Surg (1994) 0.93

Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats. J Clin Invest (1995) 0.91

Lipopolysaccharide recognition, internalisation, signalling and other cellular effects. J Endotoxin Res (2001) 0.88

Procalcitonin, C-reactive protein, and endotoxin after bone marrow transplantation: identification of children at high risk of morbidity and mortality from sepsis. Bone Marrow Transplant (2003) 0.88

Endotoxemia and elevation of lipopolysaccharide-binding protein after hematopoietic stem cell transplantation. Pediatr Infect Dis J (2003) 0.85

Antimicrobial protein rBPI21-induced surface changes on Gram-negative and Gram-positive bacteria. Nanomedicine (2013) 0.85

Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability-increasing protein and cefamandole in treatment of rabbit gram-negative sepsis. Antimicrob Agents Chemother (1996) 0.84

Deficient expression of bactericidal/permeability-increasing protein in immunocompromised hosts: translational potential of replacement therapy. Biochem Soc Trans (2011) 0.83

Protective effect of a recombinant fragment of bactericidal/permeability increasing protein against carbohydrate dyshomeostasis and tumor necrosis factor-alpha elevation in rat endotoxemia. Biochem Pharmacol (1994) 0.83

A phase I safety and pharmacokinetic study of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in healthy male volunteers. Shock (1996) 0.82

Bactericidal/permeability-increasing protein inhibits growth of a strain of Acholeplasma laidlawii and L forms of the gram-positive bacteria Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother (1999) 0.82

Deep proteome profiling of circulating granulocytes reveals bactericidal/permeability-increasing protein as a biomarker for severe atherosclerotic coronary stenosis. J Proteome Res (2012) 0.80

A novel endotoxin antagonist attenuates tumor necrosis factor-alpha secretion. J Surg Res (1996) 0.79

Pharmacokinetics of a recombinant amino terminal fragment of bactericidal/permeability increasing protein (rBPI21) after liver surgery in rats and humans. Shock (1998) 0.79

Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBPI23). Blood (1995) 0.78

Log reduction of multidrug-resistant Gram-negative bacteria by the neutrophil-derived recombinant bactericidal/permeability-increasing protein. Int J Antimicrob Agents (2013) 0.77

Identification of single nucleotide polymorphisms in hematopoietic cell transplant patients affecting early recognition of, and response to, endotoxin. Innate Immun (2013) 0.77

Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. J Clin Oncol (2008) 0.81